GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » EV-to-FCF

CGON (CG Oncology) EV-to-FCF : -21.67 (As of Mar. 16, 2025)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CG Oncology's Enterprise Value is $1,575.99 Mil. CG Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-72.72 Mil. Therefore, CG Oncology's EV-to-FCF for today is -21.67.

The historical rank and industry rank for CG Oncology's EV-to-FCF or its related term are showing as below:

CGON' s EV-to-FCF Range Over the Past 10 Years
Min: -69.25   Med: -23.47   Max: -12.17
Current: -21.67

During the past 3 years, the highest EV-to-FCF of CG Oncology was -12.17. The lowest was -69.25. And the median was -23.47.

CGON's EV-to-FCF is ranked worse than
100% of 418 companies
in the Biotechnology industry
Industry Median: 3.79 vs CGON: -21.67

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-16), CG Oncology's stock price is $27.80. CG Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.294. Therefore, CG Oncology's PE Ratio (TTM) for today is At Loss.


CG Oncology EV-to-FCF Historical Data

The historical data trend for CG Oncology's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology EV-to-FCF Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
EV-to-FCF
- - -

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -37.03 -22.47 -27.61

Competitive Comparison of CG Oncology's EV-to-FCF

For the Biotechnology subindustry, CG Oncology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CG Oncology's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where CG Oncology's EV-to-FCF falls into.



CG Oncology EV-to-FCF Calculation

CG Oncology's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1575.991/-72.721
=-21.67

CG Oncology's current Enterprise Value is $1,575.99 Mil.
CG Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-72.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CG Oncology  (NAS:CGON) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

CG Oncology's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=27.80/-1.294
=At Loss

CG Oncology's share price for today is $27.80.
CG Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.294.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


CG Oncology EV-to-FCF Related Terms

Thank you for viewing the detailed overview of CG Oncology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CG Oncology Business Description

Traded in Other Exchanges
N/A
Address
400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.